Lauxera Capital Partners
Lauxera Capital Partners is a Paris-based growth equity firm investing €20-100 million per company in commercial-stage European HealthTech companies, managing over $1 billion across two funds and 13 portfolio companies with dual offices in Paris and San Francisco.
- Company typePrivate
- Founded2020
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Lauxera Capital Partners does
Lauxera Capital Partners is a Paris-based private investment management firm founded in 2020, focused exclusively on growth equity and growth buyout investments in commercial-stage European HealthTech companies. The firm invests €20-100 million per company at the early profitability stage, targeting businesses across six HealthTech subsectors: medical devices, digital health, pharma services, life science tools, diagnostics, and HealthTech IT and data. Lauxera manages two funds—Lauxera Growth I (€260 million, closed February 2022) and Lauxera Growth II (€520 million, closed May 2026)—representing over $1 billion in total assets under management deployed across 13 portfolio companies. Revenue is generated through standard private equity economics: ~2% annual management fees on AUM and ~20% carried interest on returns above the hurdle rate.
The firm's core differentiator is its transatlantic positioning, with dual offices in Paris (41 Avenue de Friedland) and San Francisco/Mill Valley (129 Miller Ave), enabling European HealthTech portfolio companies to scale into the US market. Notable portfolio companies include OrganOx (sold to Terumo for ~$1.5 billion in August 2025), Caresyntax, Lifen, Natural Cycles, Acandis, Antaros Medical, LUMICKS, BioLamina, and Ospi. The firm is authorized by the French Autorité des Marchés Financiers (AMF) under number GP-20000005, is a UN PRI signatory, classifies all funds as SFDR Article 8, and maintains a 'Carried for Interest' policy donating a portion of carried interest to Institut Imagine for rare disease research. Lauxera is led by co-founding partners Pierre Moustial and Samuel Levy (Paris) and Alex Slack (San Francisco), supported by a team of 17 employees.
Lauxera Capital Partners firmographics
Firmographics- Name
- Lauxera Capital Partners
- Legal name
- LAUXERA CAPITAL PARTNERS
- Website
- https://lauxera.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lauxera Capital Partners is a Paris-based growth equity firm investing €20-100 million per company in commercial-stage European HealthTech companies, managing over $1 billion across two funds and 13 portfolio companies with dual offices in Paris and San Francisco.
- Ownership category
- akta.pro rank
Lauxera Capital Partners industry classification
Industry- Product category
- Growth Equity Investment Management
- NAICS
- Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)
Keywords
Where Lauxera Capital Partners is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Lauxera Capital Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Management Fees: Lauxera charges management fees on assets under management as a standard private equity/growth equity fund structure.
- Carried Interest (Performance Fees): The firm earns carried interest on fund returns above the preferred return hurdle rate. Lauxera has partnered with Institut Imagine to donate a percentage of carried interest to fund rare disease research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Lauxera Growth I - €260 million fund launched in 2021 |
| Other | Multi-year contract | Lauxera Growth II - €520 million fund closed in 2026 |
| Other | Multi-year contract | Investment ticket sizes of €20-100 million per company |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Lauxera Capital Partners product offering
Product offeringCore offering
Lauxera Capital Partners is an independent, international investment fund manager that provides growth equity and growth buyout capital (€20–100 million per company) to commercial-stage European HealthTech companies. The firm combines capital deployment with operational expertise, business development support, and talent management to help portfolio companies scale internationally, particularly into the U.S. market. It currently manages two funds — Lauxera Growth I (€260M) and Lauxera Growth II (€520M).
Product overview
Lauxera Capital Partners is an investment firm and does not offer its own products or services. The company manages two growth funds (Lauxera Growth I at €260M and Lauxera Growth II at €520M) that invest in commercial-stage European Healthtech companies. The portfolio includes 13 companies spanning medical devices (OrganOx, Acandis), digital health (Caresyntax, Lifen, Natural Cycles), pharma services (Antaros Medical, Verdot), life science tools (LUMICKS, BioLamina), diagnostics, and healthtech IT and data (Ospi, Matrix One).
Differentiator
Problem solved
Functional benefit
Brands
- Lauxera Growth I: First investment fund focused on European HealthTech companies at early profitability stage
- Lauxera Growth II
Products and services
- Lauxera Growth I Lauxera's inaugural growth equity and growth buyout fund, targeting European HealthTech companies at early profitability stage with €20–50 million tickets, supporting international commercialization particularly into the U.S. market. Aimed at institutional limited partners and deploys capital across medical devices, digital health, pharma services, life science tools, diagnostics, and HealthTech IT and data.
- Lauxera Growth II Lauxera's second growth equity fund, closed at €520 million, targeting 12 to 15 commercial-stage European HealthTech companies with €20–50 million individual investments. Provides growth capital alongside operational expertise, business development support, and talent management to help portfolio companies scale internationally into the U.S. market.
Quantifiable outcome
- +30% average portfolio topline growth
- +3 more outcomes
Companies that use Lauxera Capital Partners
Customer profileNamed customers13 records
Segments3 records
Ideal customer profiles2 records
Lauxera Capital Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Lauxera Capital Partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Institut Imaginecharitable partnerLauxera has partnered with Institut Imagine, a world-renowned research center in Paris focused on rare genetic diseases and immune disorders. Lauxera will donate a percentage of carried interest from future funds to support groundbreaking research.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Lauxera Capital Partners competitors and assessment
Company assessmentDirect peers
- Andera Partners: French private equity firm with dedicated Life Sciences and Healthcare growth strategies investing in European commercial-stage healthcare companies. Comparable in focus and check size to Lauxera.
- Wellington Partners: European venture and growth capital firm with a dedicated life sciences practice. Comparable in targeting commercial-stage European HealthTech for growth capital.
- Archimed: European healthcare-focused private equity firm investing across medical devices, life sciences, and digital health. Comparable in sector specialization and European growth-stage mandate.
- Kurma Partners: Paris-based European healthcare growth investor with active funds across HealthTech and life sciences. Comparable niche focus and European growth-stage mandate.
- Sofinnova Partners: Paris-based European healthcare/HealthTech-focused growth equity firm with multi-stage strategies across medtech, biopharma, and digital health. Closest direct competitor to Lauxera given shared Paris base, HealthTech focus, and growth-stage mandate.
- EQT Life Sciences: Amsterdam-based growth equity arm of EQT focused on European life sciences and HealthTech. Comparable in mandate, geography, and ticket size, with broader platform backing.
- Endeavor Vision: European HealthTech growth investor focusing on commercial-stage medtech and digital health companies. Closely comparable in thesis of scaling European HealthTech companies into the U.S. market.
- Forbion: European life sciences and HealthTech growth investor managing multiple funds across venture and growth stages. Directly comparable in targeting commercial-stage European healthcare companies with international scaling ambitions.
Broad incumbents
- Bain Capital Life Sciences: Global investment platform focused on life sciences and healthcare. Competes for commercial-stage European healthcare assets but operates across a much broader healthcare mandate.
- KKR Health Care Strategic Growth: Global alternative asset manager with a dedicated health care strategic growth strategy targeting commercial-stage healthcare companies. Overlaps with Lauxera in growth-stage HealthTech but at materially larger scale and broader mandate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Lauxera Capital Partners social profiles
Digital presenceLauxera Capital Partners compliance and trust
Trust signalCompliance7 records
Lauxera Capital Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lauxera Capital Partners leadership team
Management profileNumber of profiles
Profiles16 records
Lauxera Capital Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lauxera Capital Partners M&A and investment
M&A and investmentM&A3 records
Investments15 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lauxera Capital Partners
What does Lauxera Capital Partners do?
Lauxera Capital Partners is an independent, international investment fund manager that provides growth equity and growth buyout capital (€20–100 million per company) to commercial-stage European HealthTech companies. The firm combines capital deployment with operational expertise, business development support, and talent management to help portfolio companies scale internationally, particularly into the U.S. market. It currently manages two funds — Lauxera Growth I (€260M) and Lauxera Growth II (€520M).
Is Lauxera Capital Partners a public or private company?
Lauxera Capital Partners is a private company. It is classified as management employee owned and is currently operating.
When was Lauxera Capital Partners founded?
Lauxera Capital Partners was founded in 2020. It employs 11 to 50 people.
Where is Lauxera Capital Partners based?
Lauxera Capital Partners is headquartered in Paris, France, in the Europe region.
How does Lauxera Capital Partners make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest (Performance Fees).
Who are Lauxera Capital Partners's main competitors?
Direct peers on record are Andera Partners, Wellington Partners, Archimed, Kurma Partners, Sofinnova Partners, EQT Life Sciences, Endeavor Vision and Forbion. Broad incumbents are Bain Capital Life Sciences and KKR Health Care Strategic Growth.
Does Lauxera Capital Partners have an API?
No public API is recorded for Lauxera Capital Partners.
What industry is Lauxera Capital Partners in?
Lauxera Capital Partners's product category is Growth Equity Investment Management. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 5259 and its SIC code is 6282.